Published in Vaccine Weekly, September 23rd, 1996
The trial was not designed to test the efficacy of the vaccine, and recipients of the vaccine were not expected to become immune to all strains of HIV.
"Two of the volunteers were infected after [receiving] the second dose and one was infected after the third dose," said Sricharoen Migasena of the Mahidol University Faculty of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly